Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc (NDRA) pioneers advanced medical imaging through its TAEUS technology and Nexus 128 system, offering non-invasive solutions for liver diagnostics and preclinical research. This page consolidates all official announcements and third-party analyses about the company’s technological advancements and strategic initiatives.
Access real-time updates on regulatory milestones, clinical trial progress, and partnerships driving innovation in photoacoustic imaging. Investors and researchers will find detailed coverage of product developments like the TAEUS liver fat quantification system and Nexus 128’s 4D scanning capabilities.
Key updates include financial results, intellectual property filings, and collaborations with global research institutions. All content is verified for accuracy and relevance to ensure informed decision-making about this emerging leader in cost-effective diagnostic imaging.
Bookmark this page to stay informed about NDRA’s progress in addressing unmet needs in NAFLD/NASH diagnosis and expanding applications of thermo-acoustic ultrasound technology across healthcare markets.
ENDRA Life Sciences (NASDAQ: NDRA) announced its Q1 2024 financial results, reporting a net loss of $2.8 million, or $0.26 per share, a slight improvement from a $2.9 million net loss in Q1 2023. Operating expenses decreased to $2.8 million from $2.9 million due to lower R&D costs. Cash and cash equivalents stood at $1.1 million as of March 31, 2024.
Key developments include the installation of the first TAEUS system in the UK at King’s College Hospital for clinical evaluation, aimed at assessing its liver fat measurement accuracy against MRI. The study will involve approximately 75 subjects. ENDRA is also advancing its FDA De Novo application for TAEUS, with a pre-submission meeting scheduled for Q2 2024. The company expanded its intellectual property portfolio, obtaining eight new patents in Europe and China, bringing the total to 80 issued patents globally. ENDRA is exploring licensing opportunities in non-core indications to enhance its IP portfolio value.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will report financial results for the first quarter of 2024 on May 14, 2024. The company will hold a conference call and webcast to discuss the results and recent corporate developments. Participants can pre-register for the call for immediate access.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has strengthened its intellectual property with the issuance of five new international patents, including three in Europe and two in China. This brings ENDRA's IP portfolio to a milestone of 80 issued patents worldwide, protecting its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents cover innovative solutions for providing RF energy to tissue, determining material types, and monitoring tissue temperature during surgical procedures, expanding the application of TAEUS technology.
FAQ
What is the current stock price of Endra Life Sciences (NDRA)?
What is the market cap of Endra Life Sciences (NDRA)?
